Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Osimertinib for the Treatment of Metastatic EGFR T790M Mutation–Positive Non–Small Cell Lung Cancer

Clin Cancer Res (2017) 23 (9): 2131–2135.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations
  • Kiyotaka Yoh
  • Koichi Azuma
  • Hidetoshi Hayashi
  • Makoto Nishio
  • Kenichi Chikamori
  • Eiki Ichihara
  • Yasutaka Watanabe
  • Takayuki Asato
  • Tadayuki Kitagawa
  • Robert J. Fram
  • Yuichiro Ohe
International Journal of Clinical Oncology (2024) 29 (10): 1461.
Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy
  • Ping-Chih Hsu
  • John Wen-Cheng Chang
  • Li-Chung Chiu
  • Cheng-Ta Yang
  • Scott Chih‐Hsi Kuo
  • Yueh-Fu Fang
  • Chiao-En Wu
Clinical and Translational Oncology (2024)
Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
  • Wonyoung Park
  • Shibo Wei
  • Chu-Long Xie
  • Jung Ho Han
  • Bo-Sung Kim
  • Bosung Kim
  • Jung-Sook Jin
  • Eun-Sun Yang
  • Min Kyoung Cho
  • Dongryeol Ryu
  • Hao-Xian Yang
  • Sung-Jin Bae
  • Ki-Tae Ha
Experimental & Molecular Medicine (2024) 56 (5): 1137.
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
  • Bhatu R. Patil
  • Kunal V. Bhadane
  • Iqrar Ahmad
  • Yogesh J. Agrawal
  • Amit A. Shimpi
  • Mayur S. Dhangar
  • Harun M. Patel
Bioorganic & Medicinal Chemistry (2024) 109: 117796.
Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiation Therapy in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
  • Yinnan Meng
  • Han Sun
  • Sichao Wang
  • Haihua Yang
  • Feng-Ming (Spring) Kong
International Journal of Radiation Oncology*Biology*Physics (2024) 118 (2): 415.
Subgroup identification of targeted therapy effects on biomarker for time to event data
  • Gajendra K. Vishwakarma
  • Atanu Bhattacharjee
  • Fatih Tank
  • Alexander F. Pashchenko
Cancer Biomarkers (2023) 38 (4): 413.
Deuterium in drug discovery: progress, opportunities and challenges
  • Rita Maria Concetta Di Martino
  • Brad D. Maxwell
  • Tracey Pirali
Nature Reviews Drug Discovery (2023) 22 (7): 562.
Kết quả điều trị bước 2 ung thư phổi không tế bào nhỏ có đột biến T790M thứ phát bằng Osimertinib tại bệnh viện ung bướu Đà Nẵng
  • Linh Lưu
Journal of Clinical Medicine- Hue Central Hospital (2023) (91)
Design and synthesis of 4th generation EGFR inhibitors against human triple (Del19/T790M/C797S) mutation
  • Jiyoung Jeon
  • Sun Young Jang
  • Eun Joo Kwak
  • Sun Hoe Lee
  • Joo-Yun Byun
  • Yu-Yon Kim
  • Young Gil Ahn
  • Pargat Singh
  • Kyeongwon Moon
  • In Su Kim
European Journal of Medicinal Chemistry (2023) 261: 115840.
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
  • Shiyu Li
  • Shuangli Zhu
  • Hongqu Wei
  • Pengfei Zhu
  • Ying Jiao
  • Ming Yi
  • Juejun Gong
  • Kun Zheng
  • Li Zhang
Biomedicine & Pharmacotherapy (2022) 156: 113959.
Identification of phenocopies improves prediction of targeted therapy response over DNA mutations alone
  • Hamza Bakhtiar
  • Kyle T. Helzer
  • Yeonhee Park
  • Yi Chen
  • Nicholas R. Rydzewski
  • Matthew L. Bootsma
  • Yue Shi
  • Paul M. Harari
  • Marina Sharifi
  • Martin Sjöström
  • Joshua M. Lang
  • Menggang Yu
  • Shuang G. Zhao
npj Genomic Medicine (2022) 7 (1)
Chinese Herbal Medicine (Yiqi-Yangyin-Jiedu Decoction) Combined With Osimertinib as First-Line Treatment in EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (CATLA-2): A Study Protocol for a Double-Blind Randomized Controlled Trial
  • Jialin Yao
  • Yan Lu
  • Lijing Jiao
  • Ling Bi
  • Wenxiao Yang
  • Lingzi Su
  • Jun Shi
  • Zhe Wang
  • Yabin Gong
  • Ling Xu
Frontiers in Pharmacology (2022) 13
Generation of genetically engineered mice for lung cancer with mutant EGFR
  • Da-Som Kim
  • Wonjun Ji
  • Dong Ha Kim
  • Yun Jung Choi
  • Kyungtaek Im
  • Chae Won Lee
  • Jeongin Cho
  • Joongkee Min
  • Dong-Cheol Woo
  • Chang-Min Choi
  • Jae Cheol Lee
  • Young Hoon Sung
  • Jin Kyung Rho
Biochemical and Biophysical Research Communications (2022) 632: 85.
Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer
  • Yonggang Meng
  • Bin Yu
  • He Huang
  • Youmei Peng
  • Ertong Li
  • Yongfang Yao
  • Chuanjun Song
  • Wenquan Yu
  • Kaikai Zhu
  • Kai Wang
  • Dongxu Yi
  • Jinfa Du
  • Junbiao Chang
Journal of Medicinal Chemistry (2021) 64 (2): 925.
Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group
  • Mariano Provencio
  • Josefa Terrasa
  • Pilar Garrido
  • Rosario García Campelo
  • Francisco Aparisi
  • Pilar Diz
  • David Aguiar
  • Carlos García-Giron
  • Julia Hidalgo
  • Carlos Aguado
  • Jorge García González
  • Emilio Esteban
  • Lorenzo Gómez-Aldavarí
  • Teresa Moran
  • Oscar Juan
  • Luís Enrique Chara
  • Juan L. Marti
  • Rafael López Castro
  • Ana Laura Ortega
  • Elia Martínez Moreno
  • Juan Coves
  • Ana M. Sánchez Peña
  • Joaquim Bosch-Barrera
  • Amparo Sánchez Gastaldo
  • Natalia Fernández Núñez
  • Edel del Barco
  • Manuel Cobo
  • Dolores Isla
  • Margarita Majem
  • Fátima Navarro
  • Virginia Calvo
BMC Cancer (2021) 21 (1)
Delivery systems for vorinostat in cancer treatment: An updated review
  • Vu Khanh Hoa Le
  • Thi Phuong Dung Pham
  • Duy Hieu Truong
Journal of Drug Delivery Science and Technology (2021) 61: 102334.
Biological Therapies in the Treatment of Cancer—Update and New Directions
  • Monika A. Papież
  • Wirginia Krzyściak
International Journal of Molecular Sciences (2021) 22 (21): 11694.
Visible-Light-Promoted Iron-Catalyzed N-Arylation of Dioxazolones with Arylboronic Acids
  • Jing-Jing Tang
  • Xiaoqiang Yu
  • Yoshinori Yamamoto
  • Ming Bao
ACS Catalysis (2021) 11 (22): 13955.
The Security of Medical Data on Internet Based on Differential Privacy Technology
  • Zhihan Lv
  • Francesco Piccialli
ACM Transactions on Internet Technology (2021) 21 (3): 1.
BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
  • Fushun Fan
  • Minhua Zhou
  • Xiaolan Ye
  • Zhenxian Mo
  • Yaru Ma
  • Liying Luo
  • Xiaotong Liang
  • Haiqi Liu
  • Yunwo Weng
  • Mingsheng Lin
  • Xinjian Liu
  • Xiong Cai
  • Changgeng Qian
Translational Oncology (2021) 14 (2): 100961.
Clinical implementation of circulating tumour DNA testing forEGFRT790M for detection of treatment resistance in non-small cell lung cancer
  • Tara Spence
  • Sheron Perera
  • Jessica Weiss
  • Sylvie Grenier
  • Laura Ranich
  • Frances Shepherd
  • Tracy L Stockley
Journal of Clinical Pathology (2021) 74 (2): 91.
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
  • Yuan Cheng
  • Tao Zhang
  • Qing Xu
MedComm (2021) 2 (4): 692.
Calcium-activated chloride channel is involved in the onset of diarrhea triggered by EGFR tyrosine kinase inhibitor treatment in rats
  • Yumi Harada
  • Hitomi Sekine
  • Kunitsugu Kubota
  • Daichi Sadatomi
  • Seiichi Iizuka
  • Naoki Fujitsuka
Biomedicine & Pharmacotherapy (2021) 141: 111860.
The Value of Next-Generation Sequencing for Treatment in Non-Small Cell Lung Cancer Patients: The Observational, Real-World Evidence in China
  • Yan Zhang
  • Wen-Xiang Shen
  • Li-Na Zhou
  • Min Tang
  • Yue Tan
  • Chun-Xia Feng
  • Ping Li
  • Li-Qiang Wang
  • Min-Bin Chen
BioMed Research International (2020) 2020: 1.
Targeted Therapy for Non-Small Cell Lung Cancer
  • Jung Sun Kim
  • Eun Joo Kang
The Korean Journal of Medicine (2020) 95 (2): 78.
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
  • Yen-Ting Lin
  • Tzu-Hsiu Tsai
  • Shang-Gin Wu
  • Yi-Nan Liu
  • Chong-Jen Yu
  • Jin-Yuan Shih
Lung Cancer (2020) 145: 1.
A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care
  • Osama M Al-Quteimat
  • Amer M Amer
Journal of Oncology Pharmacy Practice (2020) 26 (6): 1452.
Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial–Mesenchymal Transition in Cancer
  • Monserrat Olea-Flores
  • Miriam Daniela Zuñiga-Eulogio
  • Miguel Angel Mendoza-Catalán
  • Hugo Alberto Rodríguez-Ruiz
  • Eduardo Castañeda-Saucedo
  • Carlos Ortuño-Pineda
  • Teresita Padilla-Benavides
  • Napoleón Navarro-Tito
International Journal of Molecular Sciences (2019) 20 (12): 2885.
A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer
  • Ke Huang
  • Qian Liang
  • Ye Zhou
  • Lu-lu Jiang
  • Wei-ming Gu
  • Ming-yu Luo
  • Ya-bin Tang
  • Yang Wang
  • Wei Lu
  • Min Huang
  • Sheng-zhe Zhang
  • Guang-lei Zhuang
  • Qing Dai
  • Qian-cheng Shen
  • Jian Zhang
  • Hui-min Lei
  • Liang Zhu
  • De-yong Ye
  • Hong-zhuan Chen
  • Lu Zhou
  • Ying Shen
Cell Metabolism (2019) 30 (6): 1107.
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
  • Kwai Han Yoo
  • Su Jin Lee
  • Jinhyun Cho
  • Ki Hyeong Lee
  • Keon Uk Park
  • Ki Hwan Kim
  • Eun Kyung Cho
  • Yoon Hee Choi
  • Hye Ryun Kim
  • Hoon-Gu Kim
  • Heui June Ahn
  • Ha Yeon Lee
  • Hwan Jung Yun
  • Jin-Hyoung Kang
  • Jaeheon Jeong
  • Moon Young Choi
  • Sin-Ho Jung
  • Jong-Mu Sun
  • Se-Hoon Lee
  • Jin Seok Ahn
  • Keunchil Park
  • Myung-Ju Ahn
Cancer Research and Treatment (2019) 51 (2): 718.
Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S
  • Vahideh Assadollahi
  • Behnam Rashidieh
  • Masoud Alasvand
  • Alina Abdolahi
  • J. Alejandro Lopez
Journal of Cellular Biochemistry (2019) 120 (8): 13046.
Patient Preferences for Attributes of Tyrosine Kinase Inhibitor Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer
  • John FP Bridges
  • Marie de la Cruz
  • Melissa Pavilack
  • Emuella Flood
  • Ellen M Janssen
  • Nabil Chehab
  • Ancilla W Fernandes
Future Oncology (2019) 15 (34): 3895.
Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
  • Takashi Higuchi
  • Hiromichi Oshiro
  • Zhiying Zhang
  • Kentaro Miyake
  • Norihiko Sugisawa
  • Yuki Katsuya
  • Norio Yamamoto
  • Katsuhiro Hayashi
  • Hiroaki Kimura
  • Shinji Miwa
  • Kentaro Igarashi
  • Ming Zhao
  • Michael Bouvet
  • Shree Ram Singh
  • Hiroyuki Tsuchiya
  • Robert M Hoffman
Translational Oncology (2019) 12 (4): 640.
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
  • Lauretta Odogwu
  • Luckson Mathieu
  • Kirsten B. Goldberg
  • Gideon M. Blumenthal
  • Erin Larkins
  • Mallorie H. Fiero
  • Lisa Rodriguez
  • Karen Bijwaard
  • Eunice Y. Lee
  • Reena Philip
  • Ingrid Fan
  • Martha Donoghue
  • Patricia Keegan
  • Amy McKee
  • Richard Pazdur
The Oncologist (2018) 23 (3): 353.
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
  • Apirat Chaikuad
  • Pierre Koch
  • Stefan A. Laufer
  • Stefan Knapp
Angewandte Chemie (2018) 130 (16): 4456.
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
  • Lauretta Odogwu
  • Luckson Mathieu
  • Gideon Blumenthal
  • Erin Larkins
  • Kirsten B. Goldberg
  • Norma Griffin
  • Karen Bijwaard
  • Eunice Y. Lee
  • Reena Philip
  • Xiaoping Jiang
  • Lisa Rodriguez
  • Amy E. McKee
  • Patricia Keegan
  • Richard Pazdur
The Oncologist (2018) 23 (6): 740.
Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma
  • Tyler E Miller
  • Michael Yang
  • David Bajor
  • Judah D Friedman
  • Richard Y C Chang
  • Afshin Dowlati
  • Joseph E Willis
  • Navid Sadri
Journal of Clinical Pathology (2018) 71 (12): 1108.
Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program
  • Edgardo S. Santos
  • Barry Kaplan
  • Eli Kirshner
  • Elisabeth F. Croft
  • Lecia V. Sequist
  • MyDoanh Chau
  • Jiefen Munley
  • Geoffrey R. Oxnard
Oncology and Therapy (2018) 6 (1): 45.
The Cysteinome of Protein Kinases as a Target in Drug Development
  • Apirat Chaikuad
  • Pierre Koch
  • Stefan A. Laufer
  • Stefan Knapp
Angewandte Chemie International Edition (2018) 57 (16): 4372.
Tumor-Targeted Nanoparticles Deliver a Vitamin D-Based Drug Payload for the Treatment of EGFR Tyrosine Kinase Inhibitor-Resistant Lung Cancer
  • Chang Liu
  • Tatiana Shaurova
  • Suzanne Shoemaker
  • Martin Petkovich
  • Pamela A. Hershberger
  • Yun Wu
Molecular Pharmaceutics (2018) 15 (8): 3216.
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
  • Tomomi Nakamura
  • Chiho Nakashima
  • Kazutoshi Komiya
  • Kazuki Kitera
  • Mitsuharu Hirai
  • Shinya Kimura
  • Naoko Aragane
  • Aamir Ahmad
PLOS ONE (2018) 13 (12): e0209384.
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
  • Tomoya Yokota
  • Johanna Bendell
  • Patricia LoRusso
  • Takahiro Tsushima
  • Ved Desai
  • Hirotsugu Kenmotsu
  • Junichiro Watanabe
  • Akira Ono
  • Bhavani Murugesan
  • Joseph Silva
  • Tateaki Naito
  • Jonathan Greenberg
  • Prasanna Kumar
  • Yibin Wang
  • Takahiro Jikoh
  • Ryota Shiga
  • David M. Hyman
  • Alan Loh Ho
  • David R. Spriggs
  • Gary K. Schwartz
  • Mrinal M. Gounder
British Journal of Cancer (2018) 118 (12): 1571.
Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors
  • Yanmei Peng
  • Qiang Li
  • Jingyi Zhang
  • Wen Shen
  • Xu Zhang
  • Chenyao Sun
  • Huijuan Cui
BioScience Trends (2018) 12 (6): 537.
A comprehensive review of protein kinase inhibitors for cancer therapy
  • Radhamani Kannaiyan
  • Daruka Mahadevan
Expert Review of Anticancer Therapy (2018) 18 (12): 1249.
ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway
  • Andrew M. Kidger
  • James Sipthorp
  • Simon J. Cook
Pharmacology & Therapeutics (2018) 187: 45.
Acquired Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration Samples
  • Elena Guerini-Rocco
  • Antonio Passaro
  • Chiara Casadio
  • Valeria Midolo De Luca
  • Juliana Guarize
  • Filippo de Marinis
  • Davide Vacirca
  • Massimo Barberis
Archives of Pathology & Laboratory Medicine (2018) 142 (4): 465.
Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma
  • Yuping Li
  • Hanyan Xu
  • Shanshan Su
  • Junru Ye
  • Junjie Chen
  • Xuru Jin
  • Quan Lin
  • Dongqing Zhang
  • Caier Ye
  • Chengshui Chen
  • Hyun-Sung Lee
PLOS ONE (2017) 12 (8): e0183331.
Interstitial Lung Disease Induced by Osimertinib for Epidermal Growth Factor Receptor (EGFR) T790M-positive Non-small Cell Lung Cancer
  • Yoshiya Matsumoto
  • Tomoya Kawaguchi
  • Norio Yamamoto
  • Kenji Sawa
  • Naoki Yoshimoto
  • Tomohiro Suzumura
  • Tetsuya Watanabe
  • Shigeki Mitsuoka
  • Kazuhisa Asai
  • Tatsuo Kimura
  • Naruo Yoshimura
  • Yuko Kuwae
  • Kazuto Hirata
Internal Medicine (2017) 56 (17): 2325.
Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer
  • Yvette N. Lamb
  • Lesley J. Scott
Targeted Oncology (2017) 12 (4): 555.
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine
  • Hatim Husain
  • Vladislava O. Melnikova
  • Karena Kosco
  • Brian Woodward
  • Soham More
  • Sandeep C. Pingle
  • Elizabeth Weihe
  • Ben Ho Park
  • Muneesh Tewari
  • Mark G. Erlander
  • Ezra Cohen
  • Scott M. Lippman
  • Razelle Kurzrock
Clinical Cancer Research (2017) 23 (16): 4716.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept